Endothelium-derived Vasoactive Factors and Hypertension: Possible Roles in Pathogenesis and as Treatment Targets
Tóm tắt
Từ khóa
Tài liệu tham khảo
Furchgott RF, Zawadzki JV: The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373–376.
Vanhoutte PM, Tang EHC: Endothelium-dependent contractions: when a good guy turns bad! J Physiol 2008, 586:5295–5304.
Vanhoutte PM, Tang E, Félétou M, Shimokawa H: Endothelial dysfunction and vascular disease. Acta Physiol 2009, 196:193–222.
Xu S, Touyz RM: Reactive oxygen species and vascular remodelling in hypertension: still alive. Can J Cardiol 2006, 22:947–951.
Förstermann U, Münzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708–1714.
Ryoo S, Gupta G, Benjo A, et al.: Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008, 102:923–932.
Schulz E, Jansen T, Wenzel P, et al.: Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008, 10:1115–1126.
Moens AL, Kass DA: Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006, 26:2439–2444.
• Wohlfart P, Xu H, Endlich A, Habermeier A, et al.: Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 2008, 325:370–379. This paper shows that nonpeptide compounds can enhance eNOS expression and BH 4 availability in a coordinated manner, thus preventing endothelial dysfunction and vascular disease.
Spieker LE, Flammer AJ, Lüscher TF: The vascular endothelium in hypertension. Handb Exp Pharmacol 2006, 176(Pt 2):249–283.
Sedeek M, Hébert RL, Kennedy CR, et al.: Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009, 18:122–127.
Pechanova O, Simko F: Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens 2009, 27(Suppl 6):S32–S36.
•• Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245–313. This is a state-of-the-art review on NAD(P)H oxidases.
Landmesser U, Cai H, Dikalov S, et al.: Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511–515.
Félétou M, Vanhoutte PM: Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006, 291:H985–H1002.
Mayer B, Beretta M: The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles. Br J Pharmacol 2008, 155:170–184.
• Martelli A, Breschi MC, Calderone V: Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des 2009, 15:614–636. This paper reviews the various NO donors—hybrid compounds possessing a dual activity, which have been recently synthesized and which are currently evaluated.
• Schmidt HH, Schmidt PM, Stasch JP: NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 2009, 191:309–339. This is a state-of-the-art review on soluble guanylyl cyclase activators.
• Stasch JP, Hobbs AJ: NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009, 191:277–308. This is a state-of-the-art review on soluble guanylyl cyclase stimulators.
Kass DA, Champion HC, Beavo JA: Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101:1084–1095.
Brondum E, Kold-Petersen H, Simonsen U, Aalkjaer C: NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats. Br J Pharmacol 2010, 159:154–165.
Köhler R, Kaistha BP, Wulff H: Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets 2010, 14:143–155.
•• Imig JD, Hammock BD: Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009, 8:794–805. This review provides a detailed overview about the cardiovascular effects of EETs, the anti-inflammatory and cardiovascular protective effects of sEH inhibitors, and their clinical testing.
•• Brähler S, Kaistha A, Schmidt VJ, et al.: Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 2009, 119:2323–2332. By engineering mutant mice with deletion of the genes encoding for SK Ca , IK Ca , or both, this paper demonstrates that these two endothelial potassium channels play a role in vivo in the control of vascular tone and that they contribute to the overall regulation of arterial blood pressure.
Sankaranarayanan A, Raman G, Busch C, et al.: Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 2009, 75:281–295.
Garry A, Edwards DH, Fallis IF, et al.: Ascorbic acid and tetrahydrobiopterin potentiate the EDHF phenomenon by generating hydrogen peroxide. Cardiovasc Res 2009, 84:218–226.
Félétou M: Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol 2009, 156:545–562.
• Chawengsub Y, Gauthier KM, Campbell WB: Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 2009, 297:H495–H507. This is a state-of-the-art review on the role of lipoxygenase metabolites in the endothelium-dependent regulation of vascular tone.
Hersberger M, Muller M, Marti-Jaun J, et al.: No association of two functional polymorphisms in human ALOX15 with myocardial infarction. Atherosclerosis 2009, 205:192–196.
Assimes TL, Knowles JW, Priest JR, et al.: A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis 2008, 198:136–144.
Hercule HC, Schunck WH, Gross V, et al.: Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009, 29:54–60.
Monti J, Fischer J, Paskas S, et al.: Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008, 40:529–537.
Zordoky BN, El-Kadi AO: Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010, 125:446–463.
Köhler R: Single-nucleotide polymorphisms in vascular Ca(2+)-activated K(+)-channel genes and cardiovascular disease. Pflugers Arch 2009 Dec 31 (Epub ahead of print).
Tang EHC, Félétou M, Huang Y, et al.: Acetylcholine and sodium nitroprusside cause long-term inhibition of EDCF-mediated contraction. Am J Physiol Heart Circ Physiol 2005, 289:H2434–H2440.
Michel FS, Man GS, Man RYK, Vanhoutte PM: Hypertension and the absence of EDHF-mediated responses favor endothelium-dependent contractions in renal arteries of the rat. Br J Pharmacol 2008, 13:4198–4217.
Félétou M, Vanhoutte PM, Verbeuren TJ: The thromboxane/endoperoxide receptor (TP): the common villain. J Cardiovasac Pharmacol 2010, 55:317–332.
• Tang EHC, Leung FP, Huang Y, et al.: Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. Br J Pharmacol 2007, 151:15–23. This paper demonstrates the role of abnormal endothelial calcium signaling and of COX-1-dependent generation of ROS in the production of endothelium-dependent contractions.
Wong MSK, Man RYK, Vanhoutte PM: Calcium-independent phospholipase A2 plays a key role in the endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2010, 298:H1260–H1266.
Wong MSK, Delansorne R, Man RYK, Vanhoutte PM: Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008, 295:H289–H296.
Tang EHC, Vanhoutte PM: Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics 2008, 32:409–418.
Wong SL, Leung FP, Lau CW, et al.: Cyclooxygenase-2-derivd PGF2α mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during ageing. Circ Res 2009, 104:228–235.
Rovati GE, Sala, A, Capra V, et al.: Dual COXIB/TP antagonists: a possible new twist in NASID pharmacology and cardiovascular risk. Trends Pharmacol Sci 2010, 31:102–107.
Tang EHC, Jensen B, Skott O, et al.: The role of EP and TP receptors in the response to prostaglandin E2 in the aorta of WKY and SHR. Cardiovasc Res 2008, 78:130–138.
•• Arehart E, Stitham J, Asselbergs FW, et al.: Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 2008, 102:986–993. This paper confirms in humans what has been observed in many animal models: a loss-of-function mutation in the prostacyclin receptor accelerates cardiovascular diseases.